- £218.75bn
- £236.77bn
- $54.07bn
- 78
- 14
- 98
- 73
REG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Forxiga receives positive EU CHMP opinion
AnnouncementREG - AstraZeneca PLC - Completion of divestment of US Synagis rights
AnnouncementREG - AstraZeneca PLC - AstraZeneca announces organisational changes
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Bevespi Aerosphere approved in the EU for COPD
AnnouncementREG - AstraZeneca PLC - Lynparza meets primary endpoint in SOLO-3 trial
AnnouncementREG - AstraZeneca PLC - Phase III ROCKIES and OLYMPUS roxadustat trials
AnnouncementREG - AstraZeneca PLC - FDA approves Lynparza as 1L maintenance therapy
AnnouncementREG - AstraZeneca PLC - Roxadustat approved in China for the treatment of
AnnouncementREG - AstraZeneca PLC - Directorate Change
AnnouncementREG - AstraZeneca PLC - Update on the Phase III EAGLE trial of Imfinzi
AnnouncementREG - AstraZeneca PLC - Divestment of rights to Covis completed
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Block listing Interim Review
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Grünenthal Agreement for Nexium, Vimovo Completed
AnnouncementREG - AstraZeneca PLC - US FDA grants Fasenra ODD for EGPA
AnnouncementREG - AstraZeneca PLC - AstraZeneca provides update on Phase III MYSTIC
Announcement